NBIX
Neurocrine Biosciences, Inc.
Stock
$143.18+2.47 (+1.76%)Close Oct 2, 2026
- Revenue, 2025
- $2.9B
- YoY, 2025
- +21.4%
- 5-year CAGR
- +22.3%
- 10-year CAGR
- +64.5%
Revenue
Revenue by fiscal year
| Period | Revenue | YoY |
|---|---|---|
| 2025 | $2.9B | +21.4% |
| 2024 | $2.4B | +24.8% |
| 2023 | $1.9B | +26.8% |
| 2022 | $1.5B | +31.3% |
| 2021 | $1.1B | +8.4% |
| 2020 | $1.0B | +32.7% |
| 2019 | $788M | +74.7% |
| 2018 | $451M | +179.2% |
| 2017 | $162M | +977.5% |
| 2016 | $15M | −24.1% |
| 2015 | $20M | — |
| 2014 | $0 | −100.0% |
| 2013 | $2.9M | −94.5% |
| 2012 | $53M | −31.4% |
| 2011 | $77M | +131.1% |
| 2010 | $34M | +1,034.5% |
| 2009 | $3.0M | — |